-
traditional inhibitors,
PROTACs display multiple benefits that make them
desirable drug candidates. Due to
their catalytic mechanism,
PROTACs can be administered...
- Ray Deshaies,
proteolysis targeting chimeras (
PROTACs), a new
technology to
induce proteolysis.
PROTACs are
dimeric molecules that
recruit specific intracellular...
- of
PROTACs,
which consist of a
heterobifunctional molecule with a
ligand of an E3
ubiquitin ligase linked to a
ligand of a
target protein.
PROTACs are...
-
several PROTACs degraders targeting the
androgen receptor have been
tested in the clinic:
Bavdegalutamide (ARV-110):
Developed by Arvinas, this
PROTAC is currently...
- Han X (February 2023). "Targeting
androgen receptor degradation with
PROTACs from
bench to bedside".
Biomedicine & Pharmacotherapy. 158: 114112. doi:10...
-
operating companies in France, Italy, and the UK,
working with Bayern-Chemie/
Protac in Germany,
Inmize Sistemas SL in Spain, and Saab
Bofors Dynamics in Sweden...
- the pool of
potential protein targets. Proteolysis-targeting
chimeras (
PROTACs) were
first reported by
Kathleen Sakamoto,
Craig Crews, and
Raymond Deshaies...
- It
belongs to a
class of
drugs called proteolysis targeting chimeras (
PROTACs),
which are
designed to
selectively degrade specific proteins by hijacking...
-
conceived the idea of
using heterobifunctional small molecules,
referred to as
PROTACs, to
tether cellular proteins to a
ubiquitin ligase,
resulting in ubiquitination...
- PMID 39298590.
Hamilton G,
Eggerstorfer MT,
Stickler S (2024). "Development of
PROTACS degrading KRAS and SOS1".
Oncology Research. 32 (8): 1257–1264. doi:10...
